Valid for Submission
C56.2 is a billable diagnosis code used to specify a medical diagnosis of malignant neoplasm of left ovary. The code C56.2 is valid during the fiscal year 2021 from October 01, 2020 through September 30, 2021 for the submission of HIPAA-covered transactions.
The ICD-10-CM code C56.2 might also be used to specify conditions or terms like carcinosarcoma of bilateral ovaries, carcinosarcoma of left ovary, carcinosarcoma of ovary, carcinosarcoma of right ovary, carcinosarcoma of uterine adnexa , malignant germ cell neoplasm of left ovary, etc.
The code C56.2 is applicable to female patients only. It is clinically and virtually impossible to use this code on a non-female patient.
The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10 Code Edits are applicable to this code:
The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:
- Carcinosarcoma of bilateral ovaries
- Carcinosarcoma of left ovary
- Carcinosarcoma of ovary
- Carcinosarcoma of right ovary
- Carcinosarcoma of uterine adnexa
- Malignant germ cell neoplasm of left ovary
- Malignant germ cell tumor of ovary
- Malignant neoplasm of broad ligament of uterus
- Malignant tumor involving left broad ligament by metastasis from ovary
- Malignant tumor involving right ovary by direct extension from left ovary
- Primary malignant neoplasm of both ovaries
- Primary malignant neoplasm of left ovary
- Primary malignant neoplasm of right ovary
- Secondary malignant neoplasm of broad ligament
- Secondary malignant neoplasm of pelvic peritoneum
- Secondary neoplasm of left broad ligament
- T1b : Tumor limited to both ovaries: capsule intact, no tumor on ovarian surface
Diagnostic Related Groups - MS-DRG Mapping
Convert C56.2 to ICD-9 Code
The General Equivalency Mapping (GEM) crosswalk indicates an approximate mapping between the ICD-10 code C56.2 its ICD-9 equivalent. The approximate mapping means there is not an exact match between the ICD-10 code and the ICD-9 code and the mapped code is not a precise representation of the original code.
Information for Patients
The ovaries are part of the female reproductive system. They produce a woman's eggs and female hormones. Each ovary is about the size and shape of an almond.
Cancer of the ovary is not common, but it causes more deaths than other female reproductive cancers. The sooner ovarian cancer is found and treated, the better your chance for recovery. But ovarian cancer is hard to detect early. Women with ovarian cancer may have no symptoms or just mild symptoms until the disease is in an advanced stage. Then it is hard to treat. Symptoms may include
- A heavy feeling in the pelvis
- Pain in the lower abdomen
- Bleeding from the vagina
- Weight gain or loss
- Abnormal periods
- Unexplained back pain that gets worse
- Gas, nausea, vomiting, or loss of appetite
To diagnose ovarian cancer, doctors do one or more tests. They include a physical exam, a pelvic exam, lab tests, ultrasound, or a biopsy. Treatment is usually surgery followed by chemotherapy.
NIH: National Cancer Institute
- BRCA1 and BRCA2 gene testing (Medical Encyclopedia)
- CA-125 blood test (Medical Encyclopedia)
- Ovarian Cancer (Centers for Disease Control and Prevention)
- Ovarian cancer (Medical Encyclopedia)
Ovarian cancer Ovarian cancer is a disease that affects women. In this form of cancer, certain cells in the ovary become abnormal and multiply uncontrollably to form a tumor. The ovaries are the female reproductive organs in which egg cells are produced. In about 90 percent of cases, ovarian cancer occurs after age 40, and most cases occur after age 60.The most common form of ovarian cancer begins in epithelial cells, which are the cells that line the surfaces and cavities of the body. These cancers can arise in the epithelial cells on the surface of the ovary. However, researchers suggest that many or even most ovarian cancers begin in epithelial cells on the fringes (fimbriae) at the end of one of the fallopian tubes, and the cancerous cells migrate to the ovary.Cancer can also begin in epithelial cells that form the lining of the abdomen (the peritoneum). This form of cancer, called primary peritoneal cancer, resembles epithelial ovarian cancer in its origin, symptoms, progression, and treatment. Primary peritoneal cancer often spreads to the ovaries. It can also occur even if the ovaries have been removed. Because cancers that begin in the ovaries, fallopian tubes, and peritoneum are so similar and spread easily from one of these structures to the others, they are often difficult to distinguish. These cancers are so closely related that they are generally considered collectively by experts.In about 10 percent of cases, ovarian cancer develops not in epithelial cells but in germ cells, which are precursors to egg cells, or in hormone-producing ovarian cells called granulosa cells.In its early stages, ovarian cancer usually does not cause noticeable symptoms. As the cancer progresses, signs and symptoms can include pain or a feeling of heaviness in the pelvis or lower abdomen, bloating, feeling full quickly when eating, back pain, vaginal bleeding between menstrual periods or after menopause, or changes in urinary or bowel habits. However, these changes can occur as part of many different conditions. Having one or more of these symptoms does not mean that a woman has ovarian cancer.In some cases, cancerous tumors can invade surrounding tissue and spread to other parts of the body. If ovarian cancer spreads, cancerous tumors most often appear in the abdominal cavity or on the surfaces of nearby organs such as the bladder or colon. Tumors that begin at one site and then spread to other areas of the body are called metastatic cancers.Some ovarian cancers cluster in families. These cancers are described as hereditary and are associated with inherited gene mutations. Hereditary ovarian cancers tend to develop earlier in life than non-inherited (sporadic) cases.Because it is often diagnosed at a late stage, ovarian cancer can be difficult to treat; it leads to the deaths of about 14,000 women annually in the United States, more than any other gynecological cancer. However, when it is diagnosed and treated early, the 5-year survival rate is high.